Impact of an oral gonadotropin-releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained-release gonadotropin-releasing hormone agonist : A case report.

180

1.

Thomas-Teinturier C, Allodji RS, Svetlova E et al. Ovarian reserve after

181

treatment with alkylating agents during childhood. Hum Reprod 2015; 30:

182

1437-1446.

183

2.

early-stage breast cancer. Acta Clin Croat 2019; 58: 147-156.

184

185

186

Vuković P, Kasum M, Raguž J et al. Fertility preservation in young women with

3.

Carneiro MM, Cota AM, Amaral MC et al. Motherhood after breast cancer: can

we balance fertility preservation and cancer treatment? A narrative review of the

12

literature. JBRA Assist Reprod 2018; 22: 244-252.

187

188

4.

for premenopausal breast cancer. N Engl J Med 2018; 379: 122-137.

189

190

Francis PA, Pagani O, Fleming GF et al. Tailoring adjuvant endocrine therapy

5.

Golan A, Weissman A. Symposium: Update on prediction and management of

191

OHSS. A modern classification of OHSS. Reprod Biomed Online 2009; 19:

192

28-32.

193

6.

Irahara M, Yano T, Fukaya T et al. Management and prevention of ovarian

194

hyperstimulation syndrome. Acta Obstet Gynaecol Jpn 2009; 61: 1138-1145. (in

195

Japanese)

196

7.

syndrome--views and ideas. Hum Reprod 1997; 12: 1129-1137.

197

198

8.

Soares SR. Etiology of OHSS and use of dopamine agonists. Fertil Steril 2012;

97: 517-522.

199

200

Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation

9.

Mai Q, Hu X, Yang G et al. Effect of letrozole on moderate and severe

201

early-onset ovarian hyperstimulation syndrome in high-risk women: a

202

prospective randomized trial. Am J Obstet Gynecol 2017; 216: 42.e1-10.

203

10.

Asimakopoulos B, Nikolettos N, Nehls B et al. Gonadotropin-releasing hormone

13

204

antagonists do not influence the secretion of steroid hormones but affect the

205

secretion of vascular endothelial growth factor from human granulosa luteinized

206

cell cultures. Fertil Steril 2006; 86: 636-641.

207

11.

Lee D, Kim SJ, Hong YH et al. Gonadotropin releasing hormone antagonist

208

administration for treatment of early type severe ovarian hyperstimulation

209

syndrome: a case series. Obstet Gynecol Sci 2017; 60: 449-454.

210

12.

Lainas GT, Kolibianakis EM, Sfontouris IA et al. Serum vascular endothelial

211

growth factor levels following luteal gonadotrophin-releasing hormone

212

antagonist administration in women with severe early ovarian hyperstimulation

213

syndrome. BJOG 2014; 121: 848-855.

214

13.

GnRH agonists and antagonists. Reprod Biomed Online 2002; 5 Suppl 1: 8-13.

215

216

14.

Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin

Pharmacokinet 2002; 41: 485-504.

217

218

Tarlatzis BC, Kolibianakis EM. Direct ovarian effects and safety aspects of

15.

Endo T, Honnma H, Hayashi T et al. Continuation of GnRH agonist

219

administration for 1 week, after hCG injection, prevents ovarian hyperstimulation

220

syndrome following elective cryopreservation of all pronucleate embryos. Hum

14

221

222

Reprod 2002; 17: 2548-2551.

15

223

Figure Legends

224

FIGURE 1. Details of the treatment after surgery and the controlled ovarian stimulation

225

(COS).

226

227

228

FIGURE 2. Serum estradiol (E2), progesterone (P4), follicular stimulation hormone

(FSH), luteinizing hormone (LH), and hCG levels during hospitalization.

229

230

FIGURE 3. Urine and bilateral ovary volume during hospitalization. The ovarian

231

volume was calculated from the radius of the three axes, assuming the ovary to

232

be ellipsoidal (π = 3.14 was used).

hCG

10000 U

letrozole

letrozole

2.5 mg/day

tamoxifen

5.0 mg/day

cabergoline

0.5 mg/day

hMG

20 mg/day

Leuprorelin 22.5 mg

35 h

2 Weeks

leuprorelin day 1

13

COS day 1

breast

cancer

surgery

first

visit

20

22

24

27

31

10

12

15

19

OPU

outpatient

admission

12 oocytes

(pg/mL)

(mIU/mL)

700

25

655.3

600

641.1

E2

P4

LH

FSH

hCG

20.5

20

500

434.1

400

300

10

282.6

241.1

218.5

200

100

15

13.9

2.7

0.4

admission day 1

7.1

6.2

87.3

0.2

0.1

38.3

1.1

0.1

1.4

43.4

1.2

9.45

0.1

Ringer’s lactate solution 2,000 mL/day

Heparin sodium 10,000 IU/day

Dopamine hydrochloride 3 µg/kg/min

Relugolix 40 mg/day

Paracentesis

(mL/day)

(cm3)

7000

400

urine

rt. ov

6000

lt. ov

6200

333.4

300

300

5000

259.5

4000 222.4

250

244.9

200

186.5

3000

2860

134.1 2430

123.9 122.1

143.7

2000

350

101.3

1400

1000

4 days

outpatient

150

100

80.8

1400

50

790

330

admission day 1

Ringer’s lactate solution 2,000 mL/day

Heparin sodium 10,000 IU/day

Dopamine hydrochloride 3 µg/kg/min

Relugolix 40 mg/day

Paracentesis

...